Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation
Authors:
- Michaela DöringMDMichaela Döring
- Karin Melanie Cabanillas StanchiKSKarin Melanie Cabanillas Stanchi
- Manon QueudevilleMQManon Queudeville
- Judith FeuchtJFJudith Feucht
- Franziska BlaeschkeFBFranziska Blaeschke
- Patrick SchlegelPatrick Schlegel
- Tobias FeuchtingerTFTobias Feuchtinger
- Peter LangPeter Lang
- Ingo MüllerIMIngo Müller
- Rupert HandgretingerRHRupert Handgretinger
- Werner J. HeinzWHWerner J. Heinz
- 3 March 2017
- journal article
- clinical trial
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 143 (7) , 1281-1292
Abstract
Purpose Paediatric recipients of haematopoietic stem cell transplantation (HSCT) have a high risk for invasive fungal infections. Posaconazole oral suspension has proven to be effective in antifungal prophylaxis in adult and paediatric patients. A new posaconazole tablet formulation with absorption independent of the gastric conditions was approved by the FDA in 2013. This is the first report on the use of posaconazole tablets in paediatric patients. Methods This single-centre study included 63 paediatric patients with haemato-oncological malignancies who received posaconazole for antifungal prophylaxis after HSCT. They were analysed for efficacy, feasibility and the safety of posaconazole. Out of 63 patients, 31 received posaconazole oral suspension and 32 received posaconazole tablets up to 200 days after transplantation. Analyses of the posaconazole trough levels were determined. Results No possible, probable or proven invasive fungal infection was observed in either group. Posaconazole trough levels were significantly higher in the tablet group than in the suspension group at all analysed time points. Drug-related adverse events were similarly low in both groups. Conclusions Posaconazole tablets are effective in preventing invasive fungal infections in paediatric patients. As early as day 3 after starting posaconazole tablets, over 50% of the posaconazole trough levels were >500 ng/mL, while this was observed on day 14 after start with posaconazole suspension. The administration of posaconazole tablets was safe, effective and feasible as antifungal prophylaxis in paediatric patients after HSCT.Keywords
Funding Information
- Stefan-Morsch-Stiftung, Birkenfeld, Germany
This publication has 51 references indexed in Scilit:
- Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral SuspensionAntimicrobial Agents and Chemotherapy, 2015
- Review of the New Delayed‐Release Oral Tablet and Intravenous Dosage Forms of PosaconazolePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantationEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- Posaconazole Therapeutic Drug Monitoring in Pediatric Patients and Young Adults with CancerAnnals of Pharmacotherapy, 2013
- Trends in the postmortem epidemiology of invasive fungal infections at a university hospitalJournal of Infection, 2010
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Epidemiology, Outcomes, and Costs of Invasive Aspergillosis in Immunocompromised Children in the United States, 2000Pediatrics, 2006
- Posaconazole: clinical pharmacology and potential for management of fungal infectionsExpert Review of Anti-infective Therapy, 2005
- Invasive Fungal Infections in Pediatric Oncology PatientsJournal of Pediatric Hematology/Oncology, 2005